Werkgroep Cardiologische centra Nederland

ROCKET-AF (Completed)

Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Medicine
rivaroxaban vs warfarine
Population
Arrhythmia
Phase
III
Starting year
2007

Director of Study

dr. T. Lenderink (Cardioloog)
Heerlen, Zuyderland Medisch Centrum

Publications: ROCKET-AF

  • Individualising Anticoagulant Therapy in Atrial Fibrillation PatientsArrhythm Electrophysiol Rev - Abstract - Alings, dr. A.M.W. - ROCKET-AF - Arrhythmia
  • Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary-Revision 1Eur Heart J - Abstract - Alings, dr. A.M.W. - ROCKET-AF - Arrhythmia
  • Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Circulation - Abstract - Kuijper, dr. A.F.M. - ROCKET-AF - Arrhythmia
  • EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summaryEur Heart J - Abstract - Alings, dr. A.M.W. - ROCKET-AF - Arrhythmia
  • Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AFLancet Neurol - Abstract - Kuijper, dr. A.F.M. - ROCKET-AF - Arrhythmia
  • Rivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med - Abstract - Kuijper, dr. A.F.M. - ROCKET-AF - Arrhythmia

Publications by WCN study

Publications WCN studies by WCN member